Exchange: NASDAQ·Updated 07:30 PM EST
COYA logo

COYA Coya Therapeutics Inc

$2.95
$0.03
(1.01%)
Today
Closed $2.95
$0.00
(0.00%)
After Hours
Reported EarningsNov 10
Mkt Cap$69.2M
Vol138,271.00

About COYA

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing proprietary new therapies to enhance the function of regulatory T cells. Its pipeline includes Treg Modifying Biologics, Allogeneic Treg-Derived Exosomes, and Autologous Treg Cell Therapy. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.
30

Bearish Sentiment

How do you feel about COYA?

walker7782
$COYA Recycled FUD from Oct 14. The "33%" claim is a patient misunderstanding 1:1:1 trial design (1/3 placebo, 1/3 low dose, 1/3 high dose). Coya publicly clarified weeks ago: the study remains strictly blinded and every patient received their assigned dose. If 1/3 of participants suffered actual administration errors, the DSMB/FDA would’ve issued an immediate clinical hold and mandatory 8-K. Zero holds exist. Dredging up old Facebook comments at 52-week lows is classic noise.
10
NumbingLosses
$COYA $GANX Happy Halloween, All! Have fun and be safe. Best of luck in the coming weeks/months!
10
NumbingLosses
$COYA $GANX for those of you who haven’t been watching, IOVA got completely railed sideways. This was largely due to the CEO hyping up the phase II results during the last call. Results were fine but short of the hype, and they lost a third of their MC in 30 minutes. Sometimes it’s best for CEO’s to play it conservative…
10
Jwa68
$COYA Sub 3 is probably one of the most obvious and compelling opportunities that I have personally seen in nearly 20 plus years. Still expect DRL buys them early 27. Potential for a many fold resturn in just a few short months in my mind.
6
walker7782
$COYA If you’re executing trade decisions based on anything you see on Facebook you should go back to scratch offs.
9
Jwa68
$COYA The more you know. Information is power. Do your due diligence. A 5-8 point drop over 48 weeks in itself is clinically meaningful as on average these patients would have dropped 11-13 points in 48 weeks
9
EmotionlessRobot
$COYA You'd have to ask why Clinicians and Patients pushed for the 48 week extension. This was added directly at their request. 👀👀 very bullish sign imo and statistically speaking being over enrolled means we've a better chance at showing efficacy in endpoint terms. Hopefully this treatment can stabilize ALS 🤞
8
microcapspeculator
$COYA Good news with the quarterly report. They actually have 137 in trial instead of only 120 and the only way investigators and patients ask for extension is if they thought it was working. Recent Corporate Highlights Completed enrollment of 120 planned participants in the Phase 2/3 ALSTARS trial of COYA 302 for the treatment of ALS. Coya allowed participants in screening to enter the trial. A total of 137 participants were enrolled. In response to requests from ALSTARS investigators and study participants, Coya announced plans to initiate an open-label extension (OLE) of the ALSTARS trial, providing participants who complete the 48-week study period the opportunity to continue receiving COYA 302.
1
5
Jwa68
$COYA Perspective.. Dr. Reddy's owns just under 10% of the company...cost basis is $4.40. Billionaire David Einhorn of Greenlight Capital owns about the, just under 10%. His cost basis is approximately $5.86. • Consensus Rating: Buy / Moderate Buy • Number of Analysts: 7 Price Target Estimates • Average Price Target: $15.21 to $15.33 (depending on the tracking platform) • High Price Target: $18.00 • Median Price Target: $15.50 • Low Price Target: $12.00
8
walker7782
$COYA Put it to bed, nothing to see and people need to learn how this stuff works before putting their money in the machine… * The Lake Street note confirms the dosing schedule was in place from day one—monthly drug exposure is preserved with zero impact on safety/efficacy; it's routine housekeeping. * The ClinicalTrials red/green text floating around is standard NIH track-changes. Red cut informal shorthand; green inserted exact syringe-level double-dummy specs. * Alternating active drug and dummy placebos across Wks 1 & 3 is standard double-dummy blinding. Patients don't see the unblinded manual. * Facts: ALSTARS is 14% over-enrolled (137 pts), OLE added by doctor request, $35.8M cash funds into 2H 2027, and Lake Street reiterated Buy / $17 PT. Sucks if your position is red or your short isn’t panning out. Nobody on here is moving the share price posting nonsense. Last I’ll say about any of it.
7
zampy
$COYA ONLY stock that doesnt go down .Our partner $RDY they will eventually buy us... Remember Kuly $COYA was $5 50 and $RDY was $11...2 for 1 ratio... Now $RDY ALMOST $15 $COYA NOW $3..... Stock swap 13m shares approx...about 2% dilution to $RDY WITH 835M O/S at $10....300% premium...Deals happen in this environment.... I BELIEVE FEB/MARCH
6
zampy
$COYA I believe in our management team here in spite of the price. Best team assembled on the planet, we will turn it around.
5
vo2macs
$COYA I just did some searches on Jason Lee Williams. He passed away from ALS in June. How is he posting on FB three weeks ago? The picture from his obituary does not match the picture on the posted FB profile. The FB page for the fellow posting on the COYA FB website shows a young, healthy "serial entrepreneur, and has virtually zero activity. Who is this guy?
5
AgentMulder
$COYA Nothing has changed w/science outside entire bio sector going in the toilet w/IR bumps. Same SP as 3 years ago, so I’m averaging down! 75MM MC cheap imo🤔, thx for cheapies😎
5
zampy
$COYA We have said Proteomics comes in 2H 2026...I believe WED/THURS percect time drop this biomarker data. All the right types are here. I cant always be wrong...
5
irf944
$COYA could be one of the most overlooked ALS biotech opportunities. Its 120-patient trial is fully enrolled, with results expected Q2 2027, and the new 48-week OLE could provide valuable long-term data. With Dr. Reddy’s backing, significant royalty potential, and possible buyout upside, the catalysts are compelling. COYA has a solid balance sheet with $43.2 million in cash, zero debt. Cash is expected to fund operations into the second half of 2027, beyond the anticipated ALS trial results. A relatively strong financial position heading into a major catalyst.
5
kornlover
$COYA does show the change of protocol of the design referenced in the FB post, however, it was changed prior to the start of the trial.
4
irf944
$COYA No sugar coating...the chart completely broke down. There are likely a multitude of reasons why, which i will not go into for this post. However, market conditions and bio tech micro caps is very likely one of the reasons. I brought up a 1 year chart to see if I coul d find any reason to buy and suppor the stock at these levels. What I did find was that there were 3 occasiosn this year where Coya went to oversold territory and each time it did bounce around 35% Jan 2026 stock was oversold at $3.94 and ran to $5.32 for 35% gain Mar/April stock was oversold and ran from $3.71 to $5.08 for 36% gain Aug stock was oversold and ran from $3.86 to $5.26 for a 36% gain If history repeats itself I think it is possible we see a recovery from this level back to around $4.00. Thsi time around we are way more oversold than the last 3 times. OLE has started and we have some major data early Q2. Thankfully, our cash position is very strong at over $40M and we have no debt.
4
robbied61
$COYA coya is strictly a biotechnology r d company they have no ability to retail anything no sales foce. They will advance this util they get a good partnership with a pharmaceutical company the company was formed this way from the outset . I have total confidence when this data reads out a partner will be there
3
robbied61
$COYA i am long i am savy in this space i am a big buyer nothing is wrong the volume tells u that . Bunch of buyers got hyped on news bad mkt they didn't get there trade and puked seen this movie before no what u own and stop worrying about who posted what , ,jerry garcia . One man gathers what another man spills goodbye good luck
3

Advertisement|Remove ads.